.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,660,726

« Back to Dashboard
Patent 6,660,726 protects ENJUVIA and is included in one NDA.

This patent has six patent family members in six countries.

Summary for Patent: 6,660,726

Title: Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same
Abstract:Novel estrogenic compounds of Formula I are provided. ##STR1## wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R.sub.1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R.sub.1 does not exist; R.sub.2 is lower alkyl; R.sub.3 may be selected from the group consisting of hydrogen, sulfate, or glucuronide or other esters; and R.sub.4 through R.sub.13 may independently be selected from the group consisting of hydrogen, hydroxy, ketone, lower alkyl, lower alkoxy, halogen, and carbonyl groups and R.sub.14 is selected from the group consisting of hydrogen, sulfate and glucoronide and other esters. When R.sub.1 is hydroxy, the hydroxy or ester substituent may have either an .alpha. or a .beta. orientation. Compositions of matter including compounds of the present invention are also provided as are methods of treating mammals in need of treatment using compounds of the present invention.
Inventor(s): Hill; Edward N. (Wilmington, NC), Sancilio; Frederick D. (Wilmington, NC), Whittle; Robert R. (Wilmington, NC)
Assignee: Endeavor Pharmaceuticals (Wilmington, NC)
Application Number:09/800,614
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 96th percentile
Forward Citations: 1st percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Teva Womens
ENJUVIA
estrogens, conjugated synthetic b
TABLET;ORAL021443-001Dec 20, 2004RXNo6,660,726► subscribeYY TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE
Teva Womens
ENJUVIA
estrogens, conjugated synthetic b
TABLET;ORAL021443-001Dec 20, 2004RXNo6,660,726► subscribeYY TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE
Teva Womens
ENJUVIA
estrogens, conjugated synthetic b
TABLET;ORAL021443-002Dec 20, 2004RXNo6,660,726► subscribeYY TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 6,660,726

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,227,454Estrogenic compounds, pharmaceutical compositions and formulations comprising the same► subscribe
7,179,799(3) and (6) substituted estrogenic compounds► subscribe
6,250,127 Heat-dissipating aluminum silicon carbide composite manufacturing method► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,660,726

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria377605► subscribe
Australia4733701► subscribe
Canada2402667► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc